by Lauren Comander
Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is
… Read moreAt the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more
A genetic test developed in a study at the University of Helsinki and Helsinki University Hospital identifies ovarian cancer patients who benefit from PARP inhibitors, a treatment option.
Since the therapy is associated with potential serious side-effects, it is important … Read more
by Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
by Kristi Rosa
Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.
Maintenance treatment with niraparib (Zejula) produced a sustained and
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
For … Read more
A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
